Antiarrhythmic drugs in the management of atrial fibrillation Antiarrhythmic drug therapy in the post-CAST era' 2 has undergone a period of uncertainty and re-evaluation. The role of antiarrhythmic drugs in the management of less serious arrhythmias has come into question. If an arrhythmia is not life-threatening it is paramount that it should not be made so through inappropriate treatment. This issue is particularly pertinent to the management of atrial fibrillation-the commonest of arrhythmias and one which in the absence of pre-excitation is not directly life-threatening. Yet the symptomatic limitations and morbidity imposed by atrial fibrillation are often severe and the need for effective and safe treatment is selfevident.
Digitalis, the traditional treatment, does not have a primary anti-fibrillatory action. On the contrary digitalis glycosides through their vagomimetic effects might be expected to be pro-fibrillatory.3 Not surprisingly, therefore, digoxin has been found to be no more effective than placebo in reverting atrial fibrillation to sinus rhythm. 4 In contrast class I and class III drugs in the Vaughan Williams classification do have a direct anti-fibrillatory action. Treatment is most successful in patients with recent onset of atrial fibrillation. Intravenous flecainide, for example, converted 60-80% patients with recent onset atrial fibrillation to sinus rhythm5-7 and intravenous amiodarone converted 70-80%.810 Treatment is not without potential problems. Class I agents can adversely affect ventricular function" or induce a slow atrial flutter with 1 to 1 conduction into the ventricle.'2 Intravenous amiodarone can cause hypotension."3 However, unlike long-term antiarrhythmic therapy these risks are immediate and are not a major hazard when the physician is both aware and vigilant.
In appropriately selected patients antiarrhythmic treatment is therefore a reasonable alternative to DC cardioversion. It would be unwise, however, to advocate that class I or class III agents should completely replace digoxin in the management of new onset atrial fibrillation. In some patients there is no immediate need to restore sinus rhythm and ventricular rate control alone may be adequate: digitalisation is still appropriate for this purpose. The dangers of torsades de pointes when treatment starts are well recognised and meta-analysis has suggested the possibility of an excess mortality in patients on quinidine therapy.'6 It is questionable, therefore, whether a role for quinidine in the prophylaxis of atrial fibrillation can still be justified.
Maintenance of sinus rhythm
The class Ic agents flecainide and propafenone are gaining in popularity for prophylaxis. Once again their efficacy is proven,'7-20 but can we be equally convinced about their safety? It is clear that we should avoid giving class Ic drugs to patients who resemble those recruited to CAST. Unfortunately, it is unclear which features of CAST patients predisposed them to arrhythmias. We do not know whether risks are confined to the particular patient population studied-that is, to patients with previous myocardial infarction and frequent ventricular extrasystoles-or whether they extend to all patients with previous infarction, coronary disease, or indeed any form of structural heart disease. Many patients with atrial fibrillation have underlying myocardial or coronary disease and it cannot be asserted that class Ic therapy carries no risk. Serious ventricular arrhythmias and sudden death have been reported in the management of supraventricular arrhythmias, including atrial fibrillation.2'22 While it might be anticipated that risks would be greater among patients with structural heart disease, they are not confined to this group. Life-threatening arrhythmias have also been reported among patients with lone atrial fibrillation,2' and no group of patients can be considered as completely free from risk. Despite these considerations there is no evidence of an excess in population mortality when class Ic agents are used to treat supraventricular arrhythmias.24
Class III antiarrhythmic therapy is also of proven value in prophylaxis. The archetypal agent, amiodarone, is particularly effective25 26 but has gained notoriety on account of its high incidence of side effects and occasional cases of pulmonary fibrosis. Whether this reputation is fully deserved in the management of atrial fibrillation is open to question because many patients are satisfactorily controlled on low doses of amiodarone of 200 mg daily or less. At these doses, though less serious side effects are still common, serious side effects are rare. 
